DWA
RCKT icon

Dorsey Wright & Associates’s Rocket Pharmaceuticals RCKT Stock Holding History

Dorsey Wright & Associates’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-640
Closed -$16K – 331
2018
Q3 		$16K Buy
+640
New +$13.9K ﹤0.01% 207

Other funds holding RCKT

RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BM
Bridger Management New York $150M AUM 17.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Dorsey Wright & Associates's RCKT Position: Q4 2018 in Review

Dorsey Wright & Associates sold out of Rocket Pharmaceuticals (RCKT) in Q4 2018, closing a stake of 640 shares — an estimated $16K sold.

Dorsey Wright & Associates first reported a position in RCKT in Q3 2018 and held it in 1 quarter. The position peaked at $16K in Q3 2018. 87 funds tracked by Wall St. Rank hold RCKT as of Q4 2018.

  • Dorsey Wright & Associates reported no remaining Rocket Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Dorsey Wright & Associates sold 640 Rocket Pharmaceuticals shares in Q4 2018, an estimated $16K.
  • Dorsey Wright & Associates first reported a position in Rocket Pharmaceuticals in Q3 2018 and held it in 1 quarter.
  • Dorsey Wright & Associates's Rocket Pharmaceuticals position peaked at $16K in Q3 2018.
  • 87 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q4 2018.

Based on Dorsey Wright & Associates's 13F filing for Q4 2018, filed 7 Jan 2019.